3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
9
Breast Neoplasms
9
Colorectal Neoplasms
7
Ovarian Neoplasms
5
Sarcoma
4
Prostatic Neoplasms
4
Neoplasms
4
Colonic Neoplasms
4
Melanoma
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Glioma
3
Carcinoma, Hepatocellular
3
Wilms Tumor
2
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Rectal Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Inflammation
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
palbociclib
×
Gastrointestinal
×
Clear all
NCT01907607
2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2
Completed
29 enrolled
8 charts